Tiludronate. A new treatment for an old ailment: Paget’s disease of bone

Bibliography

• FLEISCH H: Experimental basis for the use of bisphos- phonates in Paget's disease of bone. Clin. Orthop. (1987) 217:72–78.
   Google Scholar
• ••An expert and comprehensive review of the rationale forusing bisphosphonates in Paget's disease.
   Google Scholar
• SINGER FR, KRANE SM: Paget's disease of bone. In:Metabolic Bone Disease. Avioli LV, Krane SM (Eds.), Academic Press, San Diego, USA (1998):545–605.
   Google Scholar
• KANIS JA: Pathophysiology and treatment of Paget'sdisease of bone. Martin Dunitz, London, UK (1998).
   Google Scholar
• FLEISCH H, RUSSELL RGG, FRANCIS MD: Diphosphon-ates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science (1969) 165:1262–1264.
   Google Scholar
• HUGHES DE, MAC DONALD BR, RUSSELL RGG, GOWEN M: Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J. Clin. Invest. (1989) 83:1930–1935.
   Google Scholar
• •This paper provides evidence that bisphosphonates are potent inhibitors of proliferation and differentiation of osteoclast-like cells.
   Google Scholar
• FLANAGAN AM, CHAMBERS TJ: Dichloromethylene- bisphosphonate (C12MBP) inhibits bone resorption through injury to osteoclast that resorb C12MBP-coated bone. Bone Min. (1989) 6:33–43.
   PubMedGoogle Scholar
• HUGHES DE, WRIGHT KR, UY HL etal.: Bisphosphonates promote apoptosis in murine osteoclast in vitro and in vivo. J. Bone Miner. Res. (1995) 10:1478–1487.
   Google Scholar
• VITTE C, FLEISCH H, GUENTHER H. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology (1996) 137:2324–2333.
   Google Scholar
• MEUNIER PJ, VIGNOT E: Therapeutic strategy in Paget'sdisease of bone. Bone (1995) 17 (Suppl.):489–491.
   Google Scholar
• FLEISCH H. Bisphosphonates. Pharmacology and use in treatment of tumour-induced hypercalcemic and metastatic bone disease. Drugs (1991) 42:919–944.
   PubMedGoogle Scholar
• REGINSTER JY: Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone (1992) 13:351–354.
   PubMed Web of Science ®Google Scholar
• •This review contains interesting information on pharmacol-ogical and pharmacokinetic properties of tiludronate.
   Google Scholar
• BONJOUR JP, AMMANN P, BARBIER A, CAVERZASIO J, RIZZOLI R: Tiludronate: bone pharmacology and safety. Bone (1995) 17 (Suppl.):473–477.
   Google Scholar
• •A review of the literature on preclinical studies with tiludronate.
   Google Scholar
• EMONTS-ALT X, BRELIÈRE JC, RONCUCCI R: Effects of1-hydroxyethylidene-1, lbisphosphonate and (chloro-4 phenyl) thiomethylene bisphosphonic acid (SR41319B) on the mononuclear cell factor mediated release of neutral proteinases by articular chondro-cytes and synovial cells. Biochem. Pharmacol (1985) 34:4043–4049.
   PubMedGoogle Scholar
• BARBIER A, EMONTS-ALT X, BRELIÈRE JC, ETHGEN D: Invitro and in vivo osseous pharmacological profile of tiludronate. Implication for osteoporosis treatment. In: Osteoporosis. Christiansen C, Overgaard K (Eds.), Osteopress ApS Publications (1990) 2:1127–1129.
   Google Scholar
• •This study describes an elegant set of experiments showing the different mechanisms of action of tiludronate on bone resorption.
   Google Scholar
• MURAKAMI H, UDAGAWA N, TAKAHASHI N, TANAKA S, SUDA T: Tiludronate inhibits bone resorption without suppressing osteoclast formation in vitro. 4th Interna-tional Symposium on Osteoporosis. Hong Kong (1993):141.
   Google Scholar
• MURAKAMI H, TAKAHASHI N, SASAKI T et al.: A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone (1995) 17:137–144.
   PubMed Web of Science ®Google Scholar
• ••This is an important paper that provides suggestive evidencethat tiludronate is a specific inhibitor of functioning osteoclasts.
   Google Scholar
• DAVID P, NGUYEN H, BARBIER A, BARON R. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar litATPase. J. Bone Miner. Res. (1996) 11:1498–1507.
   PubMed Web of Science ®Google Scholar
• ••This study, designed to investigate the molecular modes ofaction of tiludronate, showed that the compound directly inhibit osteoclast vacuolar-ATPase-mediated proton transport.
   Google Scholar
• GODET D, HOTT M, GRAULET A, GUERIS J, MARIE P: Effects of bisphosphonates on cell proliferation, differentiation and cytokines production in rat and human calvaria osteoblastic cells (abstract). Second Workshop on Bisphosphonates. Davos, Switzerland (1994).
   Google Scholar
• TRECHSEL U, STUTZER A, FLEISCH H: Hypercalcemia induced with an arotinoid in thyroparathyroidecto-mized rats: a new model to study resorption in vivo. J. Clin. Invest. (1987) 80:1676–1686.
   Google Scholar
• AMMANN P, RIZZOLI R, CAVERZASIO J, SHIGEMATSU T,SLOSMAN D, BONJOUR JP: Effects of the bisphos-phonate tiludronate on bone resorption, calcium balance and bone mineral density. J. Bone Miner. Res. (1993) 8:1491–1498.
   PubMedGoogle Scholar
• BOONEKAMP PM, VAN DER WEE-PALS LJA, VAN WIJK-VAN LENNEP MML, THESING CW, BIJVOET OLM: Two models of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. (1986) 1:27–39.
   PubMedGoogle Scholar
• RODAN GA, SEEDOR JG, BALENA R: Preclinical pharma-cology of alendronate. Osteoporosis Int. (1993) 3 (Supp1.3) :7–12.
   Google Scholar
• SIETSEMA WK, EBETINO FH, SALVAGNO AM, BEVAN JA: Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp. Clin. Res. (1989) 15:389–396.
   PubMedGoogle Scholar
• BARBIER A, BONJOUR JP, GEUSENS P, DE VERNEJOUL MC, LACHERETZ F: Tiludronate: A bisphosphonate with a positive effect on bone quality in experimental models. J. Bone Miner. Res. (1991) 6 (Supp1.1) :217.
   Google Scholar
• EMONTS-ALT X, BARBIER A, BRELIÈRE JC, RONCUCCI R: Anti-arthritic and anti-osteoporotic activities of (chloro-4 phenyl) thiomethylene bisphosphonic acid (SR41319B). Pharmacological studies. Calcif Tissue Int. (1985) 38(Suppl.):34.
   Google Scholar
• OHNISHI H, NAKAMURA T, TSURUKAMI H, MURAKAMI H, ABE M, BARBIER A: Effect of a bisphosphonate tiludronate on bone mass and strength in established osteoporosis of ovariectomized rats. J. Bone Miner. Res. (1994) 9\(Supp1.1):267.
   Google Scholar
• MURAKAMI H, NAKAMURA T, TSURUKAMI H, ABE M, BARBIER A, SUZUKI K: Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy. J. Bone Miner. Res. (1994) 9:1355–1364.
   PubMed Web of Science ®Google Scholar
• DELMAS P, VERGNAUD P, ARLOT M, PASTOUREAU P, MEUNIER P: The in vivo anabolic effect of hPTH(1.34) is blunted when bone resorption is blocked by a bisphosphonate. J. Bone Miner. Res. (1 9 9 1) 6\(Supp1.1):136.
   Google Scholar
• DE VERNEJOUL MC, JIANG Y, LACHERETZ F et al.: Preven-tion of bone loss following tiludronate administration to ovariectomized beagle dogs. In: Osteoporosis. Christiansen C, Overgaard K (Eds.), Osteopress ApS Publica-tions (1990) 2:1119–1122.
   Google Scholar
• CHARHON S, MEUNIER P, ETHGEN D, LACHERETZ F, BRELIÈRE JC, RONCUCCI R: Histomorphometric analysis of bone biopsies of baboons treated with SR 41319B, a new bisphosphonate. Calcif Tissue Int. (1985) 38(Suppl.):33.
   Google Scholar
• GEUSENS P, NIJS J, VAN DER PERRE G et al.: Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in monkeys. J. Bone Miner. Res. (1992) 7:599–609.
   Google Scholar
• NEER RM: Skeletal safety of tiludronate. Bone (1995) 17:501S–503S.
   Google Scholar
• •This review summarises the preclinical and clinical research on the skeletal safety profile of tiludronate.
   Google Scholar
• MORALES PIGA A, DEL PINO J, RAPADO A, DIAZ-CURIEL M, PALLARES M, GONZALEZ-MACIAS J: Comparison of the efficacy and bioequivalence of two oral formula-tions of Tiludronate in the treatment of Paget's disease of bone. Clin. Therap. (1997) 19:963–974.
   PubMedGoogle Scholar
• FELS JP, GUYONNET J, BERGER Y, CAUTREELS W: Determination of SR41319, a new bisphosphonate in biological fluids by HPLC. J. Chromat (1988) 430:73–79.
   PubMed Web of Science ®Google Scholar
• SANSOM LN, NECCIARI J, THIERCELIN JF: Human pharmacokinetics of tiludronate. Bone (1995) 17 (Suppl. 5):479S–483S.
   Google Scholar
• •This article reviews the background to pharmacokinetic properties of tiludronate.
   Google Scholar
• THIERCELIN JF, ZUIDERWIJK PB, PEETERS PA et al.:Tolerance and pharmacokinetics of tiludronate after multiple doses administration of 200, 400,600 and 800 mg/day to healthy volunteers. 5th World Conference on Clinical Pharmacology and Therapeutics. Yokohama, Japan (1992).
   Google Scholar
• BOULENC X, MARTI E, JOYEUX H, ROQUES C, BERGER Y,FABRE G:: Importance of the paracellular pathway for the transport of a new bisphosphonate using the human Caco-2 monolayers model. Pharmacol Biochem. (1992) 46:1591–1600.
   Google Scholar
• FLEISCH H: Pharmacokinetic. In: Bisphosphonates inBone Disease. From the Laboratory from the Patient. (2nd Edition). Fleisch H (Ed.), The Parthenon Publishing Group, London, UK (1995).
   Google Scholar
• NECCIARI J, MOUGEOT V, PINQUIER JL, LACROIX E,ARNOUX P, DELAUTURE D: Influence of food intake (hypocalcemic or normal meal) on the bioavailability of Tiludronate. 5th World Conference on Clinical Pharma-cology and Therapeutics. Yokohama, Japan (1992).
   Google Scholar
• HYLDSTRUP L, FLESCH G, HAUFFE: Pharmacokinetic evaluation of pamidronate after oral administration: A study on dose proportionality, absolute bioavailability and effect of repeated administration. Calcif Tissue mt. (1993) 53:297–300.
   PubMedGoogle Scholar
• GERTZ BJ, HOLLAND SD, KLINE WF, MATUSZEWSKI BK,PORRAS AG: Clinical pharmacology of alendronate sodium. Osteoporosis Int. (1993) 3 (Supp1.3):13–16.
   Google Scholar
• NECCIARI J, LASCOMBES F, MONTELS R, SERRES E,ARNOUX P, DELAGOUTTE JP: Bone concentrations of tiludronic acid after single and repeated administra-tion in humans. Proceedings of the 12th International Conference on Calcium Regulating Hormones, Melbourne. Bone (1995) 16(Suppl.):197.
   Google Scholar
• AURIOLA S, FRITH J, ROGERS MJ, KOIVUNIEMI A,MONKKONEN J: Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-elecrospray mass spectrometry. J. Chrom. B (1997) 704:187–195.
   PubMedGoogle Scholar
• PAPALEXIOU P, DEBRY G, NECCIARI J, SERRES E,GOLDSTEIN N, MAIER G: Tiludronate: pharmacoki-netics in patients with Paget's disease of bone. Comparison with healthy volunteers. J. Bone Miner. Res. (1996) 11 (Suppl. 0:373.
   Google Scholar
• CHASSARD D, LASCOMBES F, CREEK R, NECCIARI J,SERRES E: Study of the pharmacokinetic interactions between tiludronate and the non-steroidal anti-inflammatory drugs: aspirin, diclofenac and indomethacin. J. Bone Miner. Res. (1996) 11 (Suppl. 1)347.
   Google Scholar
• REGINSTER JY, JEUGMANS-HUYNEN AM, ALBERT A et al. Biological and clinical assessment of a new bisphos-phonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone. Bone (1988) 9:349–354.
   PubMed Web of Science ®Google Scholar
• •First report showing that tiludronate is active in Paget's disease.
   Google Scholar
• AUDRAN M, CLOCHON P, ETHGEN D, MAZIERES B, RENTER JC: Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonate. Rheumatol. (1989) 8:71–79.
   Google Scholar
• REGINSTER JY, COLSON F, MORLOCK G, COMBE B, ETHGEN D, GEUSENS P: Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study. Arthritis Rheum. (1992) 35:967–974.
   PubMed Web of Science ®Google Scholar
• •Results of a double-blind, placebo-controlled study showing clinical and biochemical efficacy of tiludronate in a large group of Paget's disease patients.
   Google Scholar
• REGINSTER JY, TREVES R, RENTER JC et al.: Efficacy andtolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone. J. Bone Miner. Res. (1994) 9:615–619.
   PubMedGoogle Scholar
• MC CLUNG M, TOU C, GOLDSTEIN N, PICOT C: Tiludronate therapy for Paget's disease of bone. Bone (1995) 17 (Suppl.):493–496.
   Google Scholar
• •The results of a double-blind placebo-controlled study showing the safety and efficacy of 400 mg/day of tiludronate administered for 3 months in Paget's disease patients.
   Google Scholar
• FRASER WD, STAMP TC, CREEK RE, SAWYER JP, PICOT C: A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad. Med. J. (1997) 73:496–502.
   PubMed Web of Science ®Google Scholar
• •A carefully conducted double-blind placebo-controlled study demonstrating that 400 m/day of tiludronate for 3 months offers the optimum balance between efficacy and tolerance.
   Google Scholar
• ROUX C, GENNARI C, FARRERONS J et al.: Comparative, prospective, double-blind, multicenter study of the efficay of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum. (1995) 38:851–858.
   PubMed Web of Science ®Google Scholar
• ••A very well-designed and carefully conducted comparativestudy demonstrating that, in Paget's disease, tiludronate is more effective and equally safe than etidronate at equivalent doses.
   Google Scholar
• ROUX C: The methodology of clinical trials of oraltiludronate in Paget's disease of bone. Bone (1995) 17 (Supp1.5):497–499.
   Google Scholar
• REGINSTER JY, LECART MP, DEROISY R, ETHGEN D, EGELS B, FRANCHIMONT P: Paget's disease of bone treated with a Ewe day course of oral tiludronate. Ann. Rheum. Dis. (1993) 52:54–57.
   PubMedGoogle Scholar
• STAMP TC, FRASER WD, SAWYER JP, CREEK RA, PICOT C: Tiludronate Tablet (SkelidT) 400 mg/day produces lengthy clinical remission of Paget's disease: follow-up to a dose-ranging study. J. Bone Miner. Res. (1996) 11 (Supp1.1) 372.
   Google Scholar
• MORALES PIGA A, ABRAIRA SANTOS V, REY REY J, DE ABAJO IGLESIAS F: Factores que determinan la intensidad de la respuesta al tratamiento con tiludronato en la Enfermedad de Paget. Med. Clin. (1998) 110:254–258.
   PubMedGoogle Scholar
• CHAPPARD D, MINAIRE P, PRIVAT C et al: Effects oftiludronate on bone loss in paraplegic patients. J. Bone Miner. Res. (1995) 10:112–118.
   PubMedGoogle Scholar
• PETERFY CG, GENANT HK, STEINER E, KREUGER KA, LUY: Blinded radiographic evaluation of the efficacy of tiludronate disodium for the treatment of Paget's disease of bone. Proceedings of the 12th International Conference on Calcium Regulating Hormones, Melbourne. Bone (1995) 16 (Suppl.):154.
   Google Scholar
• DEVOGELAER JP, MALGHEMJ, STASSE P, NAGANT-DE-DEUXCHAISNES C: Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone. Bone (1997) 20:259–261.
   PubMedGoogle Scholar
• AUDRAN M, COMBE B, MICHAUT S, DRICOT J, DEVOGE-LAER JP, REGINSTER JY: Low risk of fractures in long-term treatment of Paget's disease of bone with tiludronate. J. Bone Miner. Res. (1996) 11 (Suppl. 1):372.
   Google Scholar
• JOHNSTON CC, ALTMAN RD, CANFIELD RE, FINERMAN GAM, TAULBEE JD, EBERT ML: Review of fracture experience during treatment of Paget's disease of bone with etidronate disodium (EHDP). Gun. Orthop. (1983) 172:186–194.
   Google Scholar
• ROUX C, LISTRAT V, VILLETTE B et al: Long-lastingdermatological lesions after tiludronate therapy. Calcif Tissue Intern. (1992) 50:378–380.
   PubMedGoogle Scholar
• PLOSKER GI, GOA KL. Clodronate. Review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs (1994) 47:945–982.
   Google Scholar
• DELMAS PD, CHAPUY MC, VIGNON E et al: Long-term effects of dichloromethylene diphosphonate in Paget's disease of bone. J. Clin. Endocrinol. Metab. (1982) 54:837–843.
   PubMed Web of Science ®Google Scholar
• HARINCK HI, BIJVOET OL, BLANKSMA HJ, DAHLINGHAUS-NIENHUYS PJ. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin. Orthop. (1987) 217:79–97.
   Google Scholar
• LUFKIN EG, ARGUETA R, WHITAKER MD et al.: Pamidronate: an unrecognized problem in gastroin-testinal tolerability. Osteoporosis Int. (1994) 4:320–322.
   PubMed Web of Science ®Google Scholar
• ADAMSON BB, GALLACHER SJ, BYARS J, RALSTON SH,BOYLE IT, BOYCE BF: Mineralisation defects with pamidronate therapy for Paget's disease. Lancet (1993) 342:1459–1460.
   PubMedGoogle Scholar
• REID IR, NICHOLSON GC, WEINSTEIN RS, HOSKING DJ, CUNDY T, KOTOWICZ MA et al.: Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized placebo-controlled trial. Am. J. Med. (1996) 171:341–348.
   Google Scholar
• HOSKING DJ, EUSEBIO RA, CHINES AA: Paget's disease of bone: Reduction of disease activity with oral risedronate. Bone (1998) 22:51–55.
   PubMed Web of Science ®Google Scholar
• BICKERSTAFF DR, DOUGLAS DL, BURKE PH, O'DOHERTYDP, KANIS JA: Improvement in the deformity of the face in Paget's disease treated with diphosphonates. J. Bone Joint Surg. (1990) 72-B:132–136.
   Google Scholar